Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AX Other antiepileptics
N03AX18 Lacosamide
D07299 Lacosamide (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Anticonvulsants
Sodium Channel Agents
Lacosamide
D07299 Lacosamide (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
1 Agents affecting nervous system and sensory organs
11 Agents affecting central nervous system
113 Antiepileptics
1139 Others
D07299 Lacosamide (JAN/USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D07299 Lacosamide
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
D07299 Lacosamide
DG01639 CYP2C19 substrate
D07299 Lacosamide
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D07299 Lacosamide
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
D07299 Lacosamide
Drug classes [BR:br08332]
Neuropsychiatric agent
DG03199 Antiepileptic agent
D07299 Lacosamide
Target-based classification of drugs [BR:br08310]
Ion channels
Voltage-gated ion channels
Sodium channels
SCN3A
D07299 Lacosamide (JAN/USAN/INN) <JP/US>
SCN9A
D07299 Lacosamide (JAN/USAN/INN) <JP/US>
SCN10A
D07299 Lacosamide (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D07299
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D07299
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D07299
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D07299
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07299
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D07299